Use of erythropoietin in the treatment of chronic inflammation
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 13, 2015
Grant Date -
Oct 25, 2007
app pub date -
Jun 11, 2007
filing date -
Nov 3, 1994
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A novel use of the known protein erythropoietin (EPO), and/or a derivative, and/or a fragment thereof, is disclosed. EPO is used as a pharmaceutical for the treatment of chronic inflammations. A particularly beneficial result is seen in patients suffering from rheumatoid arthritis (RA). Significant effects are seen in clinical variables such as morning stiffness, swollen joints, and the like.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully